LIMINATUS PHARMA, INC. Retained Earnings
LIMINATUS PHARMA, INC. (LIMN) had Retained Earnings of -$41.40 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$41.40M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$40.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$38.87M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$30.70M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$41.40M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$40.00M S-1 · filed 2026-06-24 | |
| 2025-12-31 | -$38.87M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$30.70M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$28.88M 10-Q · filed 2025-10-06 | |
| 2025-03-31 | -$1.06K 10-Q · filed 2025-06-02 | |
| 2024-12-31 | -$28.67M S-1 · filed 2026-06-24 | -$805.00 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |